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Abstract
Background: Dystrophin is a rod-shaped cytoplasmic protein that provides sarcolemmal stability as a structural link
between the cytoskeleton and the extracellular matrix via the dystrophin-associated protein complex (DAPC).
Mutations in the dystrophin-encoding DMD gene cause X-linked dystrophinopathies with variable phenotypes,
the most severe being Duchenne muscular dystrophy (DMD) characterized by progressive muscle wasting and
fibrosis. However, dystrophin deficiency does not only impair the function of skeletal and heart muscle but may
also affect other organ systems such as the brain, eye, and gastrointestinal tract. The generation of a dystrophin
reporter mouse would facilitate research into dystrophin muscular and extramuscular pathophysiology without
the need for immunostaining.
Results: We generated a DmdEGFP reporter mouse through the in-frame insertion of the EGFP coding
sequence behind the last Dmd exon 79, which is known to be expressed in all major dystrophin isoforms.
We analyzed EGFP and dystrophin expression in various tissues and at the single muscle fiber level.
Immunostaining of various members of the DAPC was done to confirm the correct subsarcolemmal location
of dystrophin-binding partners. We found strong natural EGFP fluorescence at all expected sites of
dystrophin expression in the skeletal and smooth muscle, heart, brain, and retina. EGFP fluorescence exactly
colocalized with dystrophin immunostaining. In the skeletal muscle, dystrophin and other proteins of the
DAPC were expressed at their correct sarcolemmal/subsarcolemmal localization. Skeletal muscle maintained
normal tissue architecture, suggesting the correct function of the dystrophin-EGFP fusion protein. EGFP
expression could be easily verified in isolated myofibers as well as in satellite cell-derived myotubes.
Conclusions: The novel dystrophin reporter mouse provides a valuable tool for direct visualization of dystrophin
expression and will allow the study of dystrophin expression in vivo and in vitro in various tissues by live cell imaging.
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Background
Duchenne muscular dystrophy (DMD; OMIM#310200),
the most severe form of dystrophinopathies, is a lethal
X-linked recessive disorder characterized by progressive
muscle degeneration, loss of walking ability, decline of
respiratory and cardiac function, and early death [1].
Besides the skeletal and heart muscle [2], the disease af-
fects other organs such as the central nervous system [3]
and organs which are dependent on smooth muscle
function such as the gastrointestinal [4] and the vascular
system [5]. DMD is caused by mutations in the dys-
trophin gene (DMD) that prevent the expression of
functional dystrophin. The dystrophin gene is the largest
human gene spanning 2.4 Mb at the Xp21 locus and
comprises 79 primary exons [6–8].
The main dystrophin isoform has a molecular weight
of 427 kDa and is expressed in muscle cells, where it is
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localized at the cytoplasmatic side of the sarcolemma
[9, 10]. Dystrophin has four main functional domains:
(i) the N-terminal actin-binding domain, (ii) the central
rod domain, (iii) the cysteine-rich, and (iv) the C-terminal
domain. The N-terminus and part of the dystrophin rod
domain interact with cytoskeletal actin [11, 12]. The rod
domain folds into α-helical coils composed of 24 spectrin-
like repeats interrupted by four proline-rich hinges that
lend flexibility to the protein [13, 14]. Dystrophin as-
sembles several transmembrane and cytoplasmic pro-
teins into the dystrophin-associated protein complex
(DAPC), interactions provided by the cysteine-rich and
C-terminal domains. The DAPC can be divided into (i)
the dystroglycan complex, (ii) the sarcoglycan complex,
and (iii) the cytoplasmic and extracellular matrix
(ECM) components including sarcospan, α-laminin,
syntrophins (β, γ2), dystrobrevin, and neuronal nitric
oxide synthase (nNOS) [15, 16]. The DAPC connects
the cytoskeleton with the ECM, thereby lending mech-
anical stability to the sarcolemma and protecting the
muscle from contraction-related muscle damage [9, 10].
The importance of dystrophin in DAPC assembly is
highlighted by the loss of DAPC components in DMD
muscle.
Vast progress has been made in the last two decades
to comprehend the role of dystrophin in the muscle.
Prominent contributions to the advancement of this field
have been obtained through identification and later also
the generation of animal models (e.g., mdx mice, GRMD
dogs) [17, 18].
However, despite the insight into the pathophysiology
of dystrophinopathies, DMD cannot be cured at present
and the extramuscular functions of dystrophin are not
well understood. This calls for further investigations into
the (patho)physiology of dystrophin, not only in the
muscle but also in other organs and tissues where it is
expressed. The character of DMD as a multisystem dis-
order is reflected by a large number of highly conserved
isoforms and splicing variants that differ in their cellular
and subcellular localization. The high diversity of dys-
trophin isoforms is achieved through the use of tissue-
specific promoters (Additional file 1: Figure S1). The
full-length dystrophin isoform, Dp427, is generated from
three different tissue-specific promoters: (i) muscle type
(M), which drives the expression of skeletal, cardiac, and
smooth muscle dystrophin, (ii) brain type (B), which is
active in cortical and cerebellar neurons and heart, and
(iii) Purkinje cell type (P), which regulates the cerebellar
dystrophin expression [19–22]. Shorter dystrophin iso-
forms such as the retinal (Dp260), the cerebellar and
renal (Dp140) [23], as well as the Schwann cell (Dp116)
isoforms [24] are transcribed from internal promoters.
The Dp260, Dp116, and Dp140 isoforms include parts of
the rod domain and express the cysteine-rich and C-
terminal domains, but lack the N-terminal actin-binding
domain [23–25]. The short Dp71 isoform is detected in
most non-muscle tissues including the brain, liver, kid-
ney, and lung [26–29]. Further dystrophin diversification
is achieved by alternative splicing throughout the coding
sequence of dystrophin [20, 30]. Notably, two alternative
splicing sites exist at the 3′-end of the DMD gene [31].
Their usage has been well characterized in the Dp71 iso-
form. In the Dp71d isoform, excision of exon 71 does
not alter the reading frame of the transcript and still
generates the 13-amino-acid-long C-terminus common
to most dystrophin isoforms including exon 79. The
Dp71f (Dp71b) isoform, however, is generated by alter-
native splicing of exon 78 which shifts the reading
frame and produces a C-terminus that contains 31 new
amino acids with hydrophobic properties (Additional
file 1: Figure S1). Another isoform is Dp71c lacking
exon 71-74 that encode the 110-amino-acid sequence
of the syntrophin-binding domain. Moreover, exon 78
can be additionally skipped in the latter isoform creat-
ing the Dp71Δ110 variant. The expression of these iso-
forms is differentially regulated during human embryonic
development and adulthood [20, 27, 31, 32]. Similar ex-
pression patterns have been observed in animal models on
the mRNA and protein level [20, 33]. The shortest dys-
trophin isoform, Dp40, has the same promoter as Dp71
but lacks the normal C-terminal end of Dp427. Al-
though less abundant Dp40 shows a similar expression
pattern as Dp71 [34].
In the nervous system, all the different dystrophin iso-
forms have been identified. They are expressed not only
in the adult but also during neural development. DMD
patients may suffer from CNS dysfunction including
cognitive [15, 35] and visual impairment [25, 36–38].
However, the exact role of dystrophin in the CNS as well
as its contribution to the CNS phenotype of DMD pa-
tients is still a matter of debate and hampered by the
complexity and high variety of the dystrophin isoforms
and their DAPC components: Dp427 is expressed at the
postsynapse of neurons in the hippocampus, cerebellum,
and cerebral cortex [39–43]. An involvement of this
isoform in neuronal activity as well as in the formation
and maintenance of the blood-brain barrier has been
suggested [44–47]. The Dp140 isoform is mainly
expressed during development [23]. Dp71 is expressed
in glial cells, notably in perivascular astrocytes and the
Bergmann glia of the cerebellum and in the Müller glia
of the retina that surrounds the endothelial cells [23,
48]. In the brain and retina, several authors proposed
a role of Dp71 in the maintenance of potassium and
water homeostasis as well as in the regulation of vas-
cular permeability [49–53]. In the retina, Dp427 and
Dp260 isoforms are associated with photoreceptor ter-
minals suggesting the involvement of dystrophin in
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synaptic transmission, but the precise mechanism is
still unclear [38, 54, 55].
Overall, there are still many questions to be answered
about the role of dystrophin in health and disease, espe-
cially in non-muscle tissues. Interestingly, the recent dis-
covery of a role for dystrophin in satellite cells points to
the fact that there are still unknown functions to be
found that might open new leads in DMD research [56].
Therefore, it would be beneficial to have a model organ-
ism to facilitate the study of dystrophin expression from
its natural promoter(s) in various tissues without the
need for immunostaining. Hence, we set out to generate
a DmdEGFP reporter mouse, tagging the C-terminus of
the protein with EGFP and verifying its proper subcellu-
lar expression in various mouse organs.
Methods
Generation of transgenic mice
A targeting vector was generated in order to modify the
dystrophin gene (Dmd) by inserting a FLAG and a
modified EGFP-L221K sequence [57] downstream of
the last exon 79 using the recombineering and gap re-
pair technique [58–60] (Fig. 1a). Briefly, a 10.943-kb
DNA fragment spanning intron 78, exon 79, and part
of the 3′UTR of murine Dmd was amplified from a
genomic X-chromosomal BAC clone (bMQ-389G17,
Source Bioscience Nottingham, UK) and subcloned into
the pCR-Script vector (Addgene, Cambridge, MA,
USA). Dmd exon 79 was then modified by changing the
stop codon into a leucine and inserting a FLAG-EGFP
sequence in-frame, followed by a neomycin cassette
(neo) into the 3′UTR that was flanked by two loxP sites
to enable later excision. The targeting vector was line-
arized with SalI and electroporated into 129 Ola-
derived embryonic stem (ES) cells followed by selection
with G418 (0.3 mg/ml). Correctly targeted ES clones
were selected by Southern blotting via restriction en-
zyme sites (BglII and BamHI) that had been engineered
into the construct used for homologous recombination
and were injected into C57BL/6 N blastocysts. Chimeras
were generated and mated to C57Bl/6N mice. Germline
transmission of the targeted Dmd allele was confirmed
in the F1 generation of heterozygous females via PCR
screening for the neo cassette as well as by Southern
blot analysis. The neo cassette was then removed by
crossing F1 mice with mice that ubiquitously expressed
Cre recombinase [61]. The genotype of the transgenic
DmdEGFP mice was verified via a three-primer PCR
(Fig. 1b) that allows the distinction between heterozy-
gous and homozygous animals: FW#1: 5′-TGA CTC
CCA ATA GTG GCA ACC-3′, FW#2 5′-GAG CAA
AGA CCC CAA CGA GA-3′, REV: 5′-CCA TGC GGG
AAT CAG GAG TT-3′ (wild-type = 202 bp, DmdEGFP =
304 bp). All animal experiments were conducted in
accordance with institutional guidelines for the care
and use of laboratory animals as approved by the local
authorities (LaGeSo Berlin, T 0222/13).
Isolation of EDL myofibers, culture, and differentiation of
single fiber-derived satellite cells
Extensor digitorum longus (EDL) muscles were dissected
from the hind limbs of 8-month-old DmdEGFP mice and
their wild-type littermates and digested in 0.2 % collage-
nase type I (Sigma-Aldrich, Germany) in DMEM [62].
Muscles were then transferred to DMEM-filled horse
serum (HS)-rinsed dishes using a heat-polished Pasteur
glass pipette. Muscles were triturated until the fibers had
separated, transferred to a fresh dish, and incubated at
37 °C, 5 % CO2. Intact fibers were transferred into fresh
DMEM-filled and HS-rinsed dishes using a thinly bored
Pasteur pipette and under a stereomicroscope to exclude
any cell debris. The isolated myofibers with attached satel-
lite cells (SC) were either fixed for immunofluorescence
(IF) staining or cultured in DMEM supplemented with
20 % FBS (Sigma-Aldrich), 10 % HS (Sigma-Aldrich), and
1 % chicken embryo extract (CEE Ultrafiltrate, VWR
International, Germany) in dishes that had been coated
with 10 % Matrigel® (BDBiosciences, Germany) [63]. After
2 days, SC-derived myogenic progenitors started to mi-
grate off the myofibers and formed myogenic colonies
composed of proliferating myoblasts that differentiated
into myotubes by days 6–8. This process was enhanced by
changing the growth medium to low serum medium (4 %
HS) after 5 days. Differentiating myoblasts were moni-
tored daily under the microscope and fixed after 8 days
for subsequent IF staining.
Histological analysis
Tibialis anterior (TA), EDL, quadriceps (QUAD),
gastrocnemius (GAS), and soleus (SOL) muscles, as well
as the diaphragm (DIA), heart, stomach, colon, ileum,
duodenum, brain, and eyes were dissected from 8–12-
week-old (adult) or 10-month-old (aged) male DmdEGFP
mice and from their age- and sex-matched wild-type lit-
termates. The tissue was mounted on Tissue-Tek®
O.C.T. (Hartenstein, Germany), frozen in fluid nitrogen
cooled isopentane and processed for cryostat sectioning;
8-μm cross sections were collected from the mid-belly of
the muscles and either stored at −80 °C or directly fixed
and stained. Hematoxylin/eosin staining was done accord-
ing to standard procedures.
Immunohistochemistry was performed on 8-μm cryo-
sections using the iVIEW-Ventana ABC Kit (Ventana,
AZ, USA) with primary antibodies and corresponding
biotinylated secondary antibodies using the diamino-
benzidine (DAB) visualization method. In order to sup-
press unspecific background staining, we used the
MOM kit (Vector Laboratories, Burlingame, CA, USA)
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for all primary mouse antibodies. All primary and sec-
ondary antibodies used in this study are described in
Additional file 2: Tables S1 and S2.
Immunofluorescent staining was performed on single
fibers, differentiated myoblasts, and on 8-μm cryosec-
tions from different tissues. Fibers and myoblasts were
fixed in 4 % PFA, washed, incubated 1 h at room
temperature in blocking solution containing 5 % normal
goat serum (NGS), 0.5 % BSA, and 0.2 % Triton X-100,
followed by overnight incubation with primary anti-
bodies. The cryosections were fixed in ice-cold acetone
or 4 % PFA, washed in PBS, blocked, and incubated
with primary antibodies for 1 h at room temperature or
at 4 °C overnight. After primary antibody incubation,
the samples were washed and incubated for 1 h with
fluorescently labeled secondary antibodies (AlexaFluor®
Fig. 1 Generation of the DmdEGFP reporter mouse. a Construction of the targeting vector through insertion of a FLAG-EGFP coding sequence into
the 3′UTR of the Dmd gene. The termination codon of exon 79 was altered to a leucine coding triplet. The asterisk indicates the modified exon
79. The Dmd wild-type allele was targeted in ES cells after electroporation of the SalI linearized targeting vector and subsequent homologous
recombination. Dashed lines represent homologous regions. BglII and BamHI restriction sites were artificially inserted into the construct to facilitate
identification of targeted ES cells by Southern blot analysis using either 5′ and 3′ hybridization probes (blue squares) located outside of the targeting
vector. Recombinant ES cells were then used for generation of transgenic mice. The neo cassette was removed by crossing the F1 generation
mice with ubiquitous Cre-deleter mice (constructs are not drawn to scale). b PCR genotyping of the wild-type (202 bp) and recombinant
(350 bp) allele. −/− homozygous wild-type female, y/+ hemizygous male for the DmdEGFP allele, +/− heterozygous female. c Western blot analysis of
whole TA muscle extract using dystrophin antibodies against the rod (Dys1) and the C-terminal domain (H4) with normal expression of the full-length
Dp427 dystrophin in the DmdEGFP mice. The anti-GFP antibody detected the tagged Dp427-EGFP protein only in the transgenic animal. d TA cross and
longitudinal sections show natural EGFP fluorescence (green) in DmdEGFP mice that can be detected at the sarcolemma without amplification of the
signal. No fluorescent signal above background was observed in the wild-type cross section using the identical illumination parameters
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488 and 568, Life Technologies, CA, USA, dilution 1:400),
washed in PBS, and mounted in DAPI-containing mount-
ing medium (Vectashield, Vector Laboratories, USA).
Primary antibodies in this study were directed against
the following proteins or protein subdomains: laminin, β-
spectrin, dystrophin, Dys2, MANDYS19, H4, GFP, FLAG,
GFAP, CD31, α-, β-, and γ-sarcoglycan, α-dystroglycan,
nNOS, and vinculin. Acetylcholine receptors were stained
using AlexaFluor568 coupled α-bungarotoxin. Images
were recorded with an inverted fluorescent microscope
(Leica DMI4000).
Serum CPK analysis
Blood was collected from the facial vein of 8-week-old
wild-type, DmdEGFP and mdx-mice (n = 3 of each).
Serum creatine phosphokinase (CPK) activity was mea-
sured with the Creatine Kinase Activity Assay Kit
(Sigma-Aldrich, Munich, Germany) according to the
manufacturer’s instructions.
Morphometric analysis
8 μm cryosections of the EDL and soleus muscles from
8-week-old wild-type and DmdEGFP mice were stained
with an anti-laminin antibody using the DAB
visualization method to delineate the muscle fibers.
Bright field color images were taken at ×200 magnifi-
cation and saved as TIF files. The minimal Feret diam-
eter was calculated for 500–820 fibers per muscle
using the Image-Pro Plus v.7.0 software (Media Cyber-
netics, Rockville, MD, USA). Fibers at the border of
the image were excluded from analysis. Three animals per
group were analyzed, and the fiber diameters for EDL and
soleus were plotted as a histogram (Fig. 3D).
Western blot analysis
Protein was extracted from the tibialis anterior muscle or
from the brain of 8-week-old male DmdEGFP mice and
wild-type littermates using a combination of following
two buffers (1:1) containing proteinase inhibitor cocktail:
(i) 250 mM sucrose, 10 mM Tris-HCl, pH 8.2 and (ii)
20 % SDS, 20 % glycerol, 10 % β-mercaptoethanol, 12.5 %
Western blot running buffer in bidest water; 50, 5, 0.5, or
0.05 μg protein were loaded on 3–8 % Tris-acetate gradi-
ent gels (Novex, Life Technologies), electrophoresed, and
wet-blotted onto a nitrocellulose membrane. NuPage®
LDS sample buffer (Invitrogen) was used for gel elec-
trophoresis. The blots were probed using the iBind
Flex® Western System (Invitrogen, LifeTechnologies)
with mouse antibodies directed against the dystrophin
rod domain (Dys1 or MANDYS19) and a rabbit poly-
clonal antibody against the dystrophin C-terminus
(clone H4, self-made, gift from Cyrille Vaillend) to-
gether with secondary fluorescently labeled antibodies
(AlexaFluor® 700 and 800). A second blot was probed
with a monoclonal anti-GFP antibody together with a
secondary fluorescent antibody (AlexaFluor® 700). As a
loading control, a mouse monoclonal anti-vinculin anti-
body was used. Bands were visualized using the Odys-
sey CLx system (Li-Cor) (Fig. 1c). All used antibodies
are listed in Additional file 2: Tables S1 and S2.
Results and discussion
Generation and validation of the DmdEGFP reporter mice
For generation of the DmdEGFP mice, the murine dys-
trophin locus on the X-chromosome was modified using
a targeting vector (Fig. 1a). This resulted in a modifica-
tion of dystrophin exon 79 whose natural termination
codon was removed and a C-terminal fusion protein
generated with a FLAG- and an EGFP-L221K coding se-
quence. The 3′UTR further contained a loxP flanked
neomycin (neo) cassette for ES-cell selection (Fig. 1a).
After germline transmission, the neo cassette was suc-
cessfully removed by transient crossbreeding with ubi-
quitous Cre-deleter mice. DmdEGFP transgenic animals
could be identified by allele-specific PCR (Fig. 1b).
Hemizygous males, as well as hetero- and homozygous
females were viable and fertile and were analyzed in
comparison with their wild-type littermates.
An important consideration for our targeting strategy
was the site for EGFP insertion into the endogenous
dystrophin locus. The aim was (i) to target the major
dystrophin isoforms that are expressed in most of the
relevant tissues and (ii) to find out whether the natural
endogenous dystrophin-EGFP expression would be
strong enough for detection without further amplifica-
tion by immunofluorescence. Since the FLAG-EGFP
tag was appended to the C-terminus of dystrophin, to a
protein domain where several interacting proteins bind,
we had to investigate (iii) whether the genetic manipu-
lation might cause a dystrophic phenotype per se and
whether (iv) dystrophin and its binding partners from
the DAPC would have the correct subcellular localization.
(v) Finally, we wanted to investigate whether the published
data in the literature on tissue-specific dystrophin expres-
sion patterns would correspond to those seen in our
DmdEGFP mice.
The aim of our study was to generate a reporter
mouse, in which dystrophin expression can be visual-
ized and tracked in different tissues by means of EGFP
fluorescence. Dystrophin and its numerous isoforms
and splice variants share the C-terminal domain, which
is very important for the interaction of the protein with
its binding partners and might thus interfere with
proper function; however, previous studies had already
shown that C-terminally EGFP-tagged mini- or micro-
dystrophins in transgenic mice or cells would be func-
tional [64–66]. Therefore, we inserted the FLAG-EGFP
sequence downstream of exon 79, the last exon present
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in the major dystrophin isoforms (Additional file 1: Figure
S1). Insertion of the FLAG-EGFP downstream of exon 79,
would theoretically tag the C-terminus and express the
following proteins as fusions: Dp427 (B, M, P), Dp260,
Dp140, Dp116, Dp71, Dp71d, and Dp71c. The alternative
hydrophobic C-terminus of Dp71f and Dp71Δ110 would
not be targeted in our model since skipping of exon 78
shifts the reading frame of the last exon 79 due to alterna-
tive splicing (Additional file 1: Figure S1) [31, 67]. In
addition, Dp40 expressing another alternative C-terminus
would not be tagged as well.
In order to investigate the expression pattern of the fu-
sion protein, we first analyzed the skeletal muscle of
DmdEGFP mice. The presence of the dystrophin-EGFP
fusion protein was confirmed by Western blot analysis
(Fig. 1c) using dystrophin antibodies against the rod and
C-terminal domains in TA protein lysates. The bands
from wild-type dystrophin and from dystrophin-EGFP
had similar expression intensities as detected by the rod-
domain-specific Dys1 antibody (Fig. 1c). Moreover, using
MANDYS19 as another rod-domain-specific antibody,
we compared dystrophin expression in protein extracts
from the TA muscle of normal controls and of DmdEGFP
mice over 3 orders of magnitude and found comparable
protein concentrations of the wildtype Dp427 and the
Dp427-EGFP band (Additional file 1: Figure S12). How-
ever, the band intensity of the DmdEGFP samples was
lower if the C-terminal-specific (H4, Fig. 1c) antibody
was used. A possible explanation could be a reduction of
binding affinity of the H4 antibody through steric hin-
drance by the FLAG-EGFP tag. A similar difference was
found in the Western blot of brain samples (Additional
file 1: Figure S13). The molecular sizes of the proteins
detected in both wild-type and DmdEGFP samples were
comparable since differences in molecular weight of
27.9 kDa between full-length dystrophin and dystrophin-
EGFP would not be easily detectable on Western blot at
molecular weights beyond 400 kDa. We detected an
EGFP band in the molecular size range of dystrophin
only in the muscle and brain of DmdEGFP mice (Fig. 1c,
Additional file 1: Figure S13B). Furthermore, the strong
expression of dystrophin-EGFP could be directly ob-
served under the microscope via the natural green fluor-
escence localized at the sarcolemma (Fig. 1d), while the
EGFP signal showed exact superposition with the im-
mune signal from the anti-FLAG antibody on TA sec-
tions (Fig. 2, first column).
Dystrophin-EGFP expression in skeletal muscle and
normal muscle morphology in DmdEGFP reporter mice
The correct localization of native EGFP fluorescence
was further confirmed in TA, soleus, and gastrocnemius
muscles by co-immunostaining with anti-dystrophin
antibodies against the rod (MANDYS19) and C-terminal
(Dys2) domains (Fig. 2, Additional file 1: Figure S2),
which showed an exact superposition of the signals.
MANDYS19 binds to the amino acid sequence encoded
by dystrophin exons 21-22 and thus recognizes only the
full-length protein [68]. All the alternative dystrophin
promoters that control the expression of shorter dys-
trophin isoforms are located downstream of intron 29,
and dystrophin isoforms generated from these pro-
moters would not be picked up by the MANDYS19 anti-
body. Hence, the signal from the MANDYS19 antibody,
which was similar to the signal of the Dys2 C-terminal
antibody, confirmed the correct tagging and subcellular
localization of the skeletal muscle Dp427 isoform. Cor-
rect expression of the ECM component laminin as well
as of the subsarcolemmal β-spectrin was also confirmed
on skeletal muscle sections (Additional file 1: Figure S3),
where β-spectrin colocalized with dystrophin-EGFP in
the myofibers.
Importantly, a comparison between the EGFP and
laminin signals exhibited, as expected, distinct differ-
ences, with EGFP being present at the cytoplasmatic side
of the sarcolemma and excluded from the capillaries.
Notably, the endothelial cells of the endomysial capillar-
ies were also stained by the anti-β-spectrin antibody
where dystrophin-EGFP expression was absent. This
suggests that dystrophin expression in the vascular sys-
tem is confined to larger vessels that possess a tunica
media (e.g., arteries and larger veins) [69].
The C-terminal domain of dystrophin plays an im-
portant role in the binding and assembly of the DAPC,
which has a crucial role for muscle function and sarco-
lemmal stability [70]. Adding a 27.9-kDa EGFP tag to
the C-terminus of dystrophin might hence interfere
with proper protein folding, its subcellular localization,
and protein function, thereby provoking a muscular
dystrophy such as seen in the mdx mouse model for
Duchenne muscular dystrophy (DMD). We thus inves-
tigated the skeletal muscle phenotype. H&E staining of
cross sections from different skeletal as well as from
heart muscle did not show any differences between the
adult reporter mice and their wild-type littermates
(Fig. 3a, Additional file 1: Figure S4). Moreover, no dys-
trophic changes could be detected in 10-month-old
DmdEGFP mice, which were well beyond the age when
dystrophic changes are commonly encountered in mdx
mice. For comparison, we analyzed aged-matched mdx
mice, which exhibited strong signs of fibrosis, immune
cell infiltration, and central nucleation—all hallmarks
of an advanced dystrophic process (Fig. 3a). Thus,
histological analysis confirmed that EGFP tagging of
the dystrophin C-terminus did not cause overt muscle
pathology. This notion was further confirmed by meas-
urement of normal CPK activities in the serum of
DmdEGFP mice, which were largely elevated only in the
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mdx mice (Fig. 3c). Moreover, analysis of fiber size
(minimal Feret diameters) of EDL and soleus muscles
from DmdEGFP in comparison to wild-type mice did not
reveal any significant differences (Fig. 3d).
Finally, we screened different skeletal muscles for
the expression of representative members of the vari-
ous DAPC sub-complexes. We confirmed normal
sarcolemmal/subsarcolemmal expression patterns for
α-, β-, γ-sarcoglycan, α-dystroglycan, as well as for
nNOS suggesting proper function of the fusion protein
(Fig. 3b, Additional file 1: Figures S5-S9). We conclude
that no deleterious changes of the dystrophin protein
structure might have occurred that would disturb those in-
teractions. However, for some components, it appeared as
if the expression levels would differ between DmdEGFP and
wild-type mice. However, the DAB-mediated visualization
of immune signals is not really quantitative and subject to
too many confounding factors in order to pick up subtle
differences. Here, it would be preferable in the future to
employ mass spectrometric techniques to identify and
quantify proteins that bind to the dystrophin-EGFP, which
could be easily immunoprecipitated with an anti-FLAG or
anti-GFP antibody [71].
Dystrophin-EGFP expression in cardiac and smooth muscle
Dystrophin expression in the heart is controlled by the
muscle- and brain-specific promoters, while expression
in the smooth muscles of the gastrointestinal (GI) tract
is controlled by the muscle-specific promoter. We con-
firmed correct dystrophin-EGFP expression in the heart
(Fig. 4a) as well as in the ileum (Fig. 4b) as a representa-
tive part of the GI tract through verification of colocali-
zation between the natural EGFP signal and signals
generated by anti-dystrophin antibodies. Moreover,
intramuscular cardiac blood vessels showed an EGFP
signal as well, which partially colocalized with the anti-
CD31 signal serving as a marker for endothelial cells
(Fig. 4a, right column). Dystrophin is known to be
expressed in the walls of large arteries and veins as well
as in small arteries [69], in all those vessels that are able
to regulate their vascular tone through contraction of
the smooth muscle cells in their tunica media. In con-
trast, dystrophin was absent from small veins (not
shown), whose diameter is only passively regulated by
the blood volume and elastic fibers.
The localization of dystrophin near the plasma mem-
brane of smooth muscle cells via its natural EGFP
Fig. 2 Correct localization of the EGFP-tagged dystrophin at the sarcolemma. Immunofluorescent staining of cryosections from the tibialis anterior
of DmdEGFP mice with antibodies against the FLAG-tag, C-terminal dystrophin (Dys2), rod-domain dystrophin (MANDYS19), cytoskeletal β-spectrin,
and the basement membrane protein laminin (all colored in red). Exact colocalization was observed between the natural EGFP fluorescence
(green) and the signals deriving from the two anti-dystrophin antibodies. Merged images were counterstained with DAPI (blue)
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fluorescence could be readily observed in cryosections of
other intestinal organs as well. In cross sections of stom-
ach, ileum, and duodenum of DmdEGFP mice, we ob-
served bundles of longitudinal and circular layers of
smooth muscle cells with dystrophin located at their
periphery (Additional file 1: Figure S10A). The distribu-
tion of the EGFP signal at the membrane of smooth
muscle cells was discontinuous, which is in line with
previous studies using dystrophin antibodies [24]. This
phenomenon is due to the exclusion of dystrophin from
the adherens junctions between smooth muscles [72].
Dystrophin-EGFP expression in non-muscle tissue
In order to investigate whether the different dystrophin
isoforms were tagged in non-muscle tissues as well, we
analyzed the EGFP expression in the brain and retina of
Fig. 3 DmdEGFP mice do not show signs of muscle dystrophy. a Hematoxylin and eosin (H&E) staining of tibialis anterior (TA) muscle sections from
adult (8- to 12-week-old) and aged (10-month-old) wild-type (WT) and DmdEGFP mice show normal morphology. For comparison, H&E staining of
an aged-matched mdx TA muscle shows the morphological characteristics of muscle dystrophy comprising a large variation of fiber size,
mononuclear cell infiltrates, fibrosis, and abundant centrally located myonuclei. b Wild-type and DmdEGFP mice show normal localization and
expression of the DAPC components α-dystroglycan, γ-sarcoglycan, and nNOS in TA muscle cross sections. c Serum creatine phosphokinase
(CPK) activities in the serum of wild-type, DmdEGFP, and mdx mice (n = 3 of each genotype). Values are shown as means ± S.E.M., p values were
calculated using one-way ANOVA. d The histograms depict the minimal Feret diameter of muscle fibers from EDL muscles (upper panel) and soleus
muscles (lower panel) from adult wild-type and DmdEGFP mice. Values are shown as means ± S.E.M. (n = 3 mice from each genotype were analyzed)
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DmdEGFP mice. Western blot analysis of whole brain ly-
sates from DmdEGFP mice and wild-type littermates
(Additional file 1: Figure S13) revealed only very low
levels of the full-length dystrophin Dp427 isoform using
the rod domain-specific Dys1 antibody. Similar low
levels of Dp427 could be detected with an anti-GFP anti-
body in DmdEGFP samples. The Dp140 and Dp71 iso-
forms could be detected with the C-terminal specific H4
antibody only in wild-type but not in DmdEGFP samples,
which further confirms our observation from Western
blot analysis on TA lysates that the FLAG-EGFP-tag
causes steric hindrance against binding of the H4 anti-
body. In the DmdEGFP samples, the corresponding bands,
which run at a higher molecular weight (of 170 and
100 kDa, respectively), were detected using the anti-GFP
antibody, confirming the correct targeting of the Dp427,
Dp140, and Dp71 isoforms in the brain of the DmdEGFP
mice. Furthermore, we confirmed the natural EGFP
expression in cryosections of the brain where the EGFP
signal showed exact colocalization with the immune
signal from staining with an anti-dystrophin antibody
(Fig. 5, left column).
In the retina of DmdEGFP reporter mice, EGFP expres-
sion was observed at the outer plexiform layer (OPL),
the inner limiting membrane (ILM), and sporadically at
the inner nuclear layer (INL) (Fig. 6a). A strong punctate
EGFP signal colocalized with dystrophin immunofluor-
escence and was detectable in the OPL of the retina
(Fig. 6b). Exact colocalization of the natural EGFP signal
was detected when using a C-terminal anti-dystrophin
antibody (Dys2). However, the rod domain-specific
MANDYS19 antibody did not recognize all EGFP-
positive structures confirming the targeting of different
isoforms in the retina. Although it is widely accepted
that dystrophin is expressed at the photoreceptor termi-
nals [25], a recent in-depth study of dystrophin
Fig. 4 Dystrophin-EGFP expression in heart and smooth muscle. a Colocalization at the sarcolemma of the immunofluorescent signal from
dystrophin (Dys2) and natural EGFP fluorescence (green) in heart muscle. Blood vessel endothelium is stained with anti-CD31 (red) and also
exhibits, at least, partial colocalization with the EGFP signal. b Immunofluorescent staining with a C-terminal rabbit anti-dystrophin antibody
(red) of ileum sections verifies colocalization with natural EGFP fluorescence (green). Sections were counterstained with DAPI (blue)
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expression in the retina suggested the presence of dys-
trophin also in the OPL layer, where rod and cone bipo-
lar cells of the ON-type are located. Of note, the authors
could not exclude artifacts by fluorescent signals from
neighboring regions [53]. Hence, using the DmdEGFP
mice, a better characterization of this region and the dis-
tribution of dystrophin in the retina could be achieved
without the use of antibodies and potentially associated
staining artifacts.
In the brain and retina of DmdEGFP mice, we observed
natural dystrophin-EGFP expression around blood ves-
sels that were stained with the anti-CD31 endothelial
cell marker (Figs. 5 and 6b). Moreover, staining with an
antibody against the glial fibrillary acidic protein (GFAP)
revealed partial colocalization of the dystrophin-EGFP
with the Bergmann glia in the cerebellum (Fig. 5), the
glial cells of the hippocampus (Additional file 1: Figure
S10B), and the Müller cells at the inner limiting mem-
brane of the retina (Fig. 6c). In these regions, the EGFP
signal only colocalized with the glial endfeet, which
confirms a characteristic expression pattern of the
Dp71 isoform [73]. On the other hand, dystrophin is
also expressed in the blood vessels, mainly in the wall
surrounding the endothelial cells. The EGFP signal was at
some locations exactly encircling the CD31 immunosignal
(Fig. 5), suggesting expression of the dystrophin in the
outer walls of the vessels, but not in the vascular endothe-
lium. However, from our immunofluorescent images, it
did not become entirely clear, whether the green fluores-
cence really derived from the vessel wall or from the glial
endfeet. Here, high-resolution imaging techniques like
STED microscopy could resolve the issue.
It was reported in the literature that the full-length
dystrophin isoform in the brain was expressed in neu-
rons such as in Purkinje cells of the cerebellum or in
neurons of the hippocampus [21, 74, 75]. Unfortunately,
we were unable to detect any natural EGFP fluores-
cence in the aforementioned regions using our standard
fluorescence EGFP-imaging techniques. However, via
immunostaining using an anti-GFP antibody, we de-
tected neuronal dystrophin-EGFP expression in CA1/
CA2 regions of the hippocampus and in Purkinje cells
(Additional file 1: Figure S11). The apparent absence of
natural EGFP fluorescence in the neurons of DmdEGFP
Fig. 5 Dystrophin-EGFP expression in the brain. Immunofluorescent staining of brain sections with the Dys2 antibody (red) shows colocalization
of the natural EGFP signal (green) with the dystrophin signal in the cerebellum of DmdEGFP mice. Partial colocalization of the EGFP signal with the
anti-CD31 (red) signal confirmed the presence of dystrophin expression also in the blood vessels of the brain (second column). Open arrowheads
show the EGFP signal surrounding the signal from the CD31 marker. Immunofluorescent staining with anti-glial fibrillary acidic protein (GFAP, red)
shows colocalization with the EGFP signal at the glial endfeet in the cerebellum (third column). A higher magnification of the anti-GFAP signal is
shown in the fourth column. EGFP expression is confined to the glial endfeet (asterisk), whereas the green fluorescent tag is not expressed in the
glial cell body (closed arrowheads)
Petkova et al. Skeletal Muscle  (2016) 6:25 Page 10 of 16
mice could be explained by the much lower expression
levels of the full-length Dp427 (B) dystrophin in the
brain in contrast to the Dp71 isoform, which gave
much stronger signals in the Western blot analysis
(Additional file 1: Figure S13). Moreover, immuno-
fluorescence staining with an anti-GFP antibody shows
large differences in the GFP signal intensities between
Dp71-expressing blood vessels and Dp427-expressing
neurons. For the detection of dystrophin-EGFP in the
neurons, we had to use high exposure times that led
to massive overexposure of the EGFP-positive blood
vessels (Additional file 1: Figure S11). Even after im-
munostaining with an anti-GFP antibody, using lower
exposure times to image the blood vessels would fail
to visualize the neurons.
EGFP fluorescence is detectable on the level of single
muscle fibers and in satellite cell-derived myotubes
On the level of single myofibers, we wanted to ex-
plore whether the presence of dystrophin-EGFP would
Fig. 6 Dystrophin-EGFP expression in the retina. a Presence of the natural EGFP signal in the different layers of the retina: outer plexiform layer
(OPL), inner nuclear layer (INL), and inner limiting membrane (ILM) (left image). These regions are depicted on a corresponding H&E stained cross
section from the retina of a wild-type mouse (right image). A higher magnification of the EGFP-positive regions highlighted by the squares in
a is presented in b and c. b Immunofluorescent staining with antibodies against dystrophin (Dys2, MANDYS19, red) and CD31 (red) showed
differential colocalization of natural EGFP signal (green) in the retinal OPL of DmdEGFP mice. Arrows indicate EGFP-positive retinal blood vessels
that were detected with Dys2 and anti-CD31 antibody, but not with the rod-specific antibody. Strong punctuated expression of the natural
EGFP was observed in the OPL region corresponding to the photoreceptor terminals. In this region, an exact superposition with the Dys2 signal and
some overlay with the MANDYS19 signal were observed, whereas no anti-CD31 signal was detected. c Immunofluorescent staining with antibodies
against the glial fibrillary protein (GFAP, red) showed partial colocalization with the natural EGFP signal at the ILM. Arrowheads indicate
colocalization between GFAP and EGFP at the glial endfeet. The asterisk marks the GFAP positive region, which did not express EGFP, corresponding
to the glial cell body
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allow live-cell imaging of dystrophin expression in
cultures of isolated myofibers. Indeed, freshly isolated
myofibers from DmdEGFP mice were strongly EGFP-
fluorescent and stood in stark contrast to the dark wild-
type fibers (Fig. 7a). In addition, strong dystrophin-EGFP
expression was detected at the neuromuscular junction
(NMJ) of single fibers that had been co-stained with
AlexaFluor568-labeled α-bungarotoxin, as a specific
marker for acetylcholine receptors (Fig. 7b). Hence, the
strong EGFP expression at the NMJ makes our model suit-
able for longitudinal in vivo studies on the dynamics of
dystrophin at the NMJ.
Finally, we wanted to find out whether freshly iso-
lated satellite cells cultured in vitro would express
dystrophin once they formed myotubes. Unfortu-
nately, after 8 days of culture, the natural EGFP signal
in the myotubes was too weak to be picked up by epi-
fluorescence microscopy, possibly due to the still too
low numbers of available dystrophin molecules. Inter-
estingly, using a well-established anti-GFP antibody
(Additional file 2: Table S1), the dystrophin-EGFP fu-
sion protein was detected with a much stronger signal
then using any of the anti-dystrophin antibodies
(Fig. 8). This further confirms the usefulness of our
animal model to study dystrophin expression during
myogenesis or muscle regeneration. The ability of ex
vivo satellite cells from DmdEGFP reporter mice to pro-
duce dystrophin EGFP once differentiating could serve
Fig. 7 Dystrophin-EGFP expression of single fibers. a Isolated single EDL muscle fibers from DmdEGFP mice and wild-type littermates. The natural
EGFP fluorescence (green) permits easy distinction between DmdEGFP and wild-type fibers without necessity for immunostaining. Fibers were fixed
and stained with DAPI (blue). b Natural EGFP expression at the neuromuscular junction of a single fiber co-stained with AlexaFluor568 labeled
α-bungarotoxin (BTX, red). The higher magnification shows colocalization of natural dystrophin EGFP with the acetylcholine receptor. Fibers
were counterstained with DAPI
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as a valuable tool to be exploited for transplantation
and cell tracing experiments.
Conclusion
This study describes and validates a DmdEGFP reporter
mouse that was generated through a C-terminal
dystrophin-EGFP fusion protein, which is expressed
from its natural promoters. The addition of the tag did
not have any influence on the structure and function of
the protein and the assembly of the dystrophin-
associated protein complex. The natural EGFP expres-
sion is strong enough in the skeletal, heart, and smooth
muscles, brain, and retina allowing detection of dys-
trophin even on the single fiber level without the need
for immunofluorescent staining. We confirmed the suc-
cessful targeting of the major dystrophin isoforms that
express the last exon 79. The mouse model will provide
better insight into the normal dystrophin expression in
the muscle as well as in the non-muscle tissue and will
facilitate studies on the dynamics of dystrophin expres-
sion. Furthermore, the crossing of the DmdEGFP allele
into the mdx background in cis (e.g., the Dmd exon 23
nonsense mutation lies on the same allele as the FLAG-
EGFP tag) will provide an excellent model to investigate
dystrophin re-expression in vivo or ex vivo after various
gene therapy protocols that are aimed at the re-
establishment of the dystrophin open reading frame or
in naturally occurring revertant fibers.
Additional files
Additional file 1: Figures S1-S13. Figure S1. Targeting of various
dystrophin isoforms in DmdEGFP mice. A schematic representation of
known dystrophin isoforms and splice variants and their alternative C-
termini; in DmdEGFP mice, the FLAG-EGFP sequence is fused to the exon
79 coding sequence of Dmd. We expected successful targeting of the iso-
forms Dp427 (M, B, P), Dp260, Dp140, Dp116, Dp71, Dp71d, and Dp71c.
The alternatively spliced variants of Dp71, namely Dp71f, Dp71Δ110, and
Dp40 contain an alternative C-terminus that does not contain the coding
sequence of exon 79 and hence cannot be tagged with EGFP. Dark blue
squares show the alternative C-terminal sequence generated by skipping
of exon 78. Due to alternative splicing, the C-terminus of Dp40 is entirely
different and fails to express EGFP as well. M, muscle-specific promoter; B,
brain-specific promoter; P, Purkinje cell promoter; N, N-terminus; C, C-
terminus of the polypeptide chain. Figure S2. Correct localization of the
EGFP-tagged dystrophin at the sarcolemma. Immunofluorescent staining
of cross sections from soleus (SOL), gastrocnemius (GAS), and tibialis
anterior (TA) muscles of transgenic mice with anti-dystrophin antibodies
specific to (A) the C-terminal domain (Dys2), (B) the rod domain
(MANDYS19); all colored in red. Exact colocalization was observed
between the natural EGFP fluorescence (green) and the signals deriving
from the two anti-dystrophin antibodies. Figure S3. Correct localization
of the EGFP-tagged dystrophin at the sarcolemma. Immunofluorescent
staining of cross sections from soleus (SOL), gastrocnemius (GAS), and
tibialis anterior (TA) muscles of transgenic mice with anti-dystrophin
antibodies specific to (A) cytoskeletal β-spectrin and (B) the basement
membrane protein laminin; all colored in red. Figure S4. Absence of a
dystrophic phenotype in H&E stained skeletal and heart muscle of adult
and aged wild-type (WT) and DmdEGFP mice. Skeletal muscles quadriceps
(QUAD), gastrocnemius (GAS), extensor digitorum longus (EDL), soleus
(SOL), diaphragm (DIA), and heart muscle from adult wild-type and
transgenic mice show normal morphology with consistency in fiber caliber
and no evidence for the presence of central nuclei, fibrosis, or the presence
Fig. 8 Dystrophin-EGFP expression of satellite cell-derived myotubes. Dystrophin-EGFP expression of in vitro differentiated satellite cells; isolated
single fibers with their attached satellite cells from wild-type (WT) and DmdEGFP mice were cultured for 4 days and differentiated for a further
8 days. Forming myotubes were fixed and stained with anti-GFP (green) and Dys2 (red) antibodies and counterstained with DAPI (blue)
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of inflammatory cells. No further changes are observed in aged mice in the
QUAD, GAS, EDL, and heart muscle. Figure S5. Immunohistochemistry of
skeletal muscles of wild-type (WT) and DmdEGFP mice with an antibody
against α-sarcoglycan. Normal sarcolemmal expression of α-sarcoglycan can
be observed in the following skeletal muscles: gastrocnemius (GAS), soleus
(SOL), tibialis anterior (TA), quadriceps (QUAD), and extensor digitorum longus
(EDL). Figure S6. Immunohistochemistry of skeletal muscles of wild-type
(WT) and DmdEGFP mice with an antibody against β-sarcoglycan.
Normal sarcolemmal expression of β-sarcoglycan can be observed in
the following skeletal muscles: gastrocnemius (GAS), soleus (SOL), tibialis
anterior (TA), quadriceps (QUAD), and extensor digitorum longus (EDL).
Figure S7. Immunohistochemistry of skeletal muscles of wild-type (WT)
and DmdEGFP mice with an antibody against γ-sarcoglycan. Normal
sarcolemmal expression of γ-sarcoglycan can be observed in the following
skeletal muscles: gastrocnemius (GAS), soleus (SOL), tibialis anterior (TA),
quadriceps (QUAD), and extensor digitorum longus (EDL). Figure S8.
Immunohistochemistry of skeletal muscles of wild-type (WT) and DmdEGFP
mice with an antibody against α-dystroglycan. Normal sarcolemmal expression
of α-dystroglycan can be observed in the following skeletal muscles:
gastrocnemius (GAS), soleus (SOL), tibialis anterior (TA), quadriceps
(QUAD), and extensor digitorum longus (EDL). Figure S9. Immuno-
histochemistry of skeletal muscles of wild-type (WT) and DmdEGFP mice
with an antibody against nNOS. Normal sarcolemmal expression of nNOS
can be observed in the following skeletal muscles: gastrocnemius (GAS),
soleus (SOL), tibialis anterior (TA), quadriceps (QUAD), and extensor digitorum
longus (EDL). Figure S10. EGFP expression in the smooth muscle and in the
hippocampus. (A) Sections from the stomach, duodenum, and colon of
DmdEGFP mice were stained with DAPI (blue). Strong natural EGFP expression
(green) was detectable in the circular and longitudinal muscular layers.
(B) Immunofluorescent staining of brain sections with an anti-glial
fibrillary acidic protein antibody (GFAP, red) shows colocalization with
the EGFP signal (green) at the glial endfeet in the hippocampus;
counterstaining with DAPI (blue). A higher magnification is shown in
the right column. Figure S11. EGFP expression in the hippocampus
and in the cerebellum. (A) Left: Overview with DAPI staining of the
mouse hippocampus with the CA1-3 regions and the dentate gyrus
(DG). The dashed square is zoomed in on the right side. Neuronal
cells (asterisk) of the DmdEGFP mouse show much lower full-length
dystrophin-EGFP expression than the blood vessels (arrowhead) as
visualized by immunostaining with an anti-GFP antibody (green). Due
to the high expression differences, the images are depicted with two
different exposure times. (B) The same pattern can be observed in the
cerebellum of DmdEGFP mice stained with anti-GFP antibody (green).
Dystrophin-EGFP expression in the Purkinje cells (asterisks) can be detected
only with higher exposure times. All sections are counterstained with DAPI
(blue). Figure S12.Western blot analysis of full-length dystrophin expression.
A western blot of different amounts (50, 5, 0.5, 0.05 μg) of whole protein
extracts from the TA muscle of wild-type and DmdEGFP-mice was probed
with a dystrophin antibody against the rod domain (MANDYS19) and
against vinculin as loading control. Both wild-type and transgenic mice
show comparable dystrophin protein expression levels. Figure S13.
Western blot analysis of dystrophin-EGFP expression in the brain.
Western blot analysis of whole brain lysates using antibodies specific against
the rod domain (Dys1) and the C-terminal domain (H4) of dystrophin, as
well as an anti-GFP antibody. Two different contrast settings were used
(A, B) in order to identify different dystrophin isoforms in the brain, which
are expressed at different levels. (A) Dp71 is detected using the H4 antibody
in the wild-type samples. The targeted isoform Dp71-EGFP shows a band
running at 100 kDa detected by the anti-GFP antibody. (B) Higher contrast
enhancement of the blot show Dp427 full-length dystrophin in wild-type
and transgenic samples using the Dys1 antibody. The anti-GFP antibody also
detected the targeted full-length form. Dp140 is detected using the H4
antibody in the wild-type samples. The targeted isoform Dp140-EGFP shows
a band running at 170 kDa which is detected by the anti-GFP antibody.
Vinculin served as loading control. WT, wild-type. (PDF 1438 kb)
Additional file 2: Tables S1-S2. Table S1: Primary antibodies. Table
S2: Secondary antibodies. (DOC 70 kb)
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